U.S. Launches Pharma Pricing Probe Against Germany

The United States Trade Representative (USTR) launched a Section 301 investigation into Germany's pharmaceutical pricing system on June 18, 2026. The probe aims to determine if Germany's policies result in "persistent underpayment for innovative pharmaceutical products" that unfairly burdens or restricts U.S. commerce. This action signals a broader shift in U.S. trade policy to challenge foreign domestic regulatory regimes, raising concerns about potential tariffs and retaliatory measures.

The USTR alleges that Germany's pricing practices, including supplemental discounts and mandatory rebates, suppress pharmaceutical prices below fair market value. As a result, U.S. consumers reportedly pay approximately 3.9 times more than German consumers for brand-name drugs, effectively subsidizing a disproportionate share of global pharmaceutical research and development (R&D) costs. The investigation will also examine pending German legislation that could impose additional rebates on patented medicines starting in 2027.

Germany's pharmaceutical pricing system, known as AMNOG, allows new drugs to launch at an initial free price for six months, followed by benefit assessments and price negotiations between manufacturers and health insurers. Reference pricing is also used for older or non-innovative drugs to cap reimbursement levels. German Chancellor Friedrich Merz has rejected the notion that Washington should influence Germany's domestic healthcare policy.

The Section 301 investigation could lead to various outcomes, including targeted or broad-based tariffs on German exports. This probe comes despite a U.S.-EU trade deal that caps most EU goods, including pharmaceuticals, at 15% with "no stacking" of tariffs. However, a separate Section 232 action has already imposed tariffs of up to 100% on patented drugs and active pharmaceutical ingredients (APIs), with some taking effect on July 31, 2026. The USTR has requested consultations with Germany and scheduled a public hearing for September 22, 2026.

For informational purposes only. Not investment advice.

Source: BRZ News research desk. Disclaimer: For informational and educational purposes only and does not constitute financial, investment, or trading advice.